No profile data available.
Immunic, Inc. (IMUX) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in New York, United States, with about 100 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$97.17 million. Its market capitalization was $111.75 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany.
Immunic reported $0 in revenue for fiscal year 2025.
$111.75 million as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Century Therapeutics, Inc. (IPSC), Cue Biopharma, Inc. (CUE), Nkarta, Inc. (NKTX), Adicet Bio, Inc. (ACET).